Institutional Biosafety Committee (IBC)

The Weill Cornell Medical College IBC's primary responsibility is to work with the WCMC research community to ensure that recombinant DNA (including transgenic animal and human gene transfer) research conducted at WCMC is carried out in accordance with the NIH Guidelines for Research Involving Recombinant DNA Molecules.

The IBC also reviews non-recombinant DNA research involving agents classified as Risk Group 2, 3, and 4 in the NIH Guidelines, Appendix B and non-recombinant DNA research involving select agents as listed by the CDC (Right-click and choose "Save Link As" to view).

WCMC IBC meetings are open to the public. WCMC reserves the right to hold executive sessions during IBC meetings. Executive sessions are not open to the public.